Gilead Sciences Stock Analysis: Don’t Lump Gilead Sciences In With The Biotech Bubble

  • Gilead Sciences has not had the incredible breakout one would expect from its blowout earnings report.
  • The company’s management team has proven to be extremely capable and has a tendency to keep expectations low and soundly beating them.
  • The HCV franchise has given the company enough financial flexibility to fund future growth in case the current drug pipeline does not come through.
  • I Know First algorithm is bullish on Gilead Sciences over the next year, believing that it is certain to climb to new all-time highs
Based on the last price level, I Know First algorithm is bullish on this company going forward, believing it will surpass its all-time high and breakout to new levels from there.

Read The Full Seeking Alpha Article